Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.

Tom Rosenberg Kee Kiat Yeo Audrey Mauguen Sanda Alexandrescu Sanjay P Prabhu Jessica W Tsai Seth Malinowski Mrinal JoshiraoKarishma ParikhSameer Farouk SaitMarc K RosenblumJamal K Benhamida George MichaielHung N TranSonika M DahiyaKara KachurakGregory K Friedman Julie I KrystalMichael A HuangAshley S Margol Karen D WrightDolly AguileraTobey J MacDonaldSusan N ChiMatthias A Karajannis

Published in: Neuro-oncology (2022)

Upfront targeted therapy for patients with BRAF-mutant pHGG is feasible and effective, with superior clinical outcomes compared to historical data. This promising treatment paradigm is currently being evaluated prospectively in the Children's Oncology Group ACNS1723 clinical trial.

Keyphrases

high grade
clinical trial
wild type
cancer therapy
young adults
randomized controlled trial
low grade
electronic health record
machine learning
drug delivery
big data
single molecule
metastatic colorectal cancer
deep learning
data analysis